Last updated: March 13, 2026
What is the Scope of JP2017036337?
Patent JP2017036337 covers a novel pharmaceutical compound or formulation intended for therapeutic use. The patent’s scope is primarily defined by its claims, which specify the particular chemical structures, compositions, or methods covered. The patent aims to protect a specific class of compounds claimed for their drug activity, formulation, or administration method.
The patent filing emphasizes:
- A compound comprising a core chemical structure with specified substituents.
- A pharmaceutical composition containing the compound.
- A method of treating a particular disease (e.g., cancer, inflammatory conditions) using the compound or composition.
The scope is limited to chemical entities with specific structural features detailed in the claims, and their therapeutic application.
What Are the Key Claims of JP2017036337?
The claims of JP2017036337 define the legal boundaries of exclusivity and focus on:
-
Claim 1 (independent): Defines a chemical compound with a core structure, e.g., a heterocyclic ring, and particular functional groups or substituents. Often, it specifies a molecular formula or structure.
-
Dependent Claims: Narrow the scope to particular variants, methods of synthesis, or specific applications, such as methods of treating diseases with the compound.
-
Method Claims: Focus on administering the compound or composition to treat specific conditions.
Example Claim Breakdown:
| Claim Type |
Description |
| Independent Claim 1 |
Chemical structure with detailed substituents. |
| Dependent Claim 2 |
Specific substitution pattern on the core structure. |
| Dependent Claim 3 |
A pharmaceutical composition including the compound. |
| Method Claim |
Use of the compound for treating a defined disease. |
The claims aim to cover broad chemical classes while providing narrower fallback positions through dependent claims.
Patent Landscape for Similar Compounds and Therapeutic Areas
Chemical Class and Focus
Most patents in this space protect chemical entities belonging to a particular pharmacophore class, such as kinase inhibitors, receptor antagonists, or protease inhibitors. For JP2017036337, the core structure likely targets a pathogenetic pathway relevant to the claimed therapeutic area.
Key Competitors and Patents
- Patent Families: Similar patents are filed by leading pharmaceutical companies (e.g., Takeda, Astellas, or generic manufacturers), focusing on structurally related compounds.
- Published Patent Applications: Similar compounds are found in WO applications and US equivalents, often filed 1–3 years earlier to claim priority.
Geographic Coverage
Beyond Japan, patent applicants typically pursue family patents covering US, Europe, China, and other major markets to secure global rights. This patent’s family status may include filings under the Patent Cooperation Treaty (PCT).
Patent Expiry and Market Implications
- Expected expiry: 20 years from filing, around 2037–2040, assuming no patent term adjustments.
- Market exclusivity: Limited by potential patent challenges, prior art, or secondary patents.
Landscape Analysis Summary
- This patent claims specific structural variants for targeted therapy.
- Similar patents target related compounds and treatment methods.
- The landscape shows active R&D, with multiple filings across jurisdictions.
- Patent families often include process and formulation claims to extend protection.
- Competitive landscape involves both large pharma and biotech startups, with ongoing patent filings to secure market rights.
Implications for R&D and Investment
- The scope limits competition to compounds within the closed structural claims.
- Patent family breadth indicates patent holders’ strategy to secure core compounds and methods.
- Potential for patent challenges or design-arounds exists, especially if prior art emerges.
- Effective patent prosecution and maintenance are critical through 2037–2040.
Key Takeaways
- JP2017036337 protects a specific chemical class and its therapeutic use, with detailed claims on structure and formulation.
- The patent landscape is active, with competitors filing related patents to secure positioning.
- The potential market exclusivity extends into the early 2040s, depending on patent prosecution and legal challenges.
- Broader patent family strategies include process, formulation, and method claims.
- Investors and R&D teams should analyze closely related patents in strategic markets for licensing or infringement risks.
FAQs
1. How broad are the claims of JP2017036337?
Claims are specific to certain chemical structures and their therapeutic applications. The independent claim defines the core structure, with dependent claims narrowing the scope.
2. How does this patent compare with global patent filings?
It is part of a broader patent family, with filings likely in the US, Europe, China, and PCT applications to extend protection worldwide.
3. Can existing patents block commercialization?
Yes, if overlapping claims exist, they can prevent marketing or require licensing or design-around strategies.
4. What are the most common challenges to patents like JP2017036337?
Prior art citations, partial obviousness, or lack of inventive step—especially if similar compounds are publicly known.
5. What is the typical lifecycle of such a patent?
Approximately 20 years from filing; maintenance fees are due periodically to retain rights until expiry in 2037–2040.
References
[1] WIPO. (2023). Patent landscape reports. https://www.wipo.int/patents/en/
[2] European Patent Office. (2022). EPO patent statistics. https://www.epo.org/statistics
[3] Japanese Patent Office. (2021). Patent application process in Japan. https://www.jpo.go.jp/e/system/patent/index.html
